June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Biochemical Analysis of Potential c-Cbl Antagonists Identified through an in silico Screen
Author Affiliations & Notes
  • Brian P Ceresa
    Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, United States
    Ophthalmology and Vision Sciences, University of Louisville, Louisville, Kentucky, United States
  • John O Trent
    James Brown Cancer Center, University of Louisville, Louisville, Kentucky, United States
  • Footnotes
    Commercial Relationships   Brian Ceresa, None; John Trent, None
  • Footnotes
    Support  NIH Grant EY027032
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2621. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brian P Ceresa, John O Trent; Biochemical Analysis of Potential c-Cbl Antagonists Identified through an in silico Screen. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2621. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Activation of the Epidermal Growth Factor Receptor (EGFR) is critical in corneal epithelial regeneration and homeostasis. The clinical use of EGFR ligands (e.g. epidermal growth factor – EGF) are not reliable tools to restore and maintain the epithelial layer, likely due to high endogenous EGF levels and intrinsic mechanisms of receptor down-regulation. One mediator of EGFR down-regulation is the E3 ubiquitin ligase, c-Cbl. Ubiquitylation of the EGFR targets it for lysosomal degradation; using RNAi to attenuate c-Cbl expression enhanced the kinetics of corneal epithelial wound healing. We postulate that supplementing the relatively high, endogenous levels of EGF (~2-3 ng/ml) in human tears with a c-Cbl antagonist will prevent EGFR down-regulation and enhance receptor activity and promote homeostasis of the epithelial layer. In this study, we identify and test potential c-Cbl antagonist for binding and inhibitory activity.

Methods : Using published crystal structures of the EGFR and c-Cbl and their domains of interaction, 25,000,000 compounds were screened using an in silico assay. The top candidates were identified and tested for binding to recombinant c-Cbl using a Thermofluor® assay. EGFR ubiquitylation was measured by treating immortalized human corneal epithelial cells with EGF, immunoprecipitating the receptor, and immunoblotting for the presence of conjugated ubiquitin.

Results : Of the ranked compounds, 50 were tested for binding to recombinant c-Cbl. Four of these bound to c-Cbl as indicated by a shift in the Thermofluor® fluorescence profile. Of these four compounds, one resulted in a decrease in ligand-mediated EGFR ubiquitylation.

Conclusions : We have initiated our screen of potential c-Cbl antagonists and identified four compounds that directly bind c-Cbl. One compound prevents ligand-mediated EGFR ubiquitylation. Since liganded EGFRs that do not get ubiquitylated are diverted from the lysosome for degradation, EGFR signaling is sustained. This compound is a promising, first-generation c-Cbl antagonist that circumvents the limitations of exogenous ligands as a corneal epithelial wound healing therapy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.